SCHEMBL721464

SCHEMBL721464

CCc1nn(-c2ccc(OC)cc2)cc1C(O)C1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 5/20 0.42
HTT P42858 2/20 0.42
RAB9A P51151 1/20 0.41
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
P2RX7 Q99572 1/20 0.39
ADORA3 P0DMS8 1/20 0.37
MAPT P10636 1/20 0.36
GFER P55789 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SLC6A9 P48067 1/20 0.36
LMNA P02545 1/20 0.35
CYP11B2 P19099 1/20 0.35
EPHX2 P34913 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716549 0.90 RAB9A (0.40) KDM4EALDH1A1HTTRAB9ASLC6A2
SCHEMBL719184 0.88 PDE4A (0.43) KDM4EALDH1A1HTTMAPTSMN1; SMN2
SCHEMBL720503 0.85 IDO1 (0.42) KDM4EALDH1A1HTTRAB9ASLC6A2
SCHEMBL718670 0.84 SMN1; SMN2 (0.43) KDM4EALDH1A1HTTSMN1; SMN2LMNA
SCHEMBL717911 0.83 PDE2A (0.39) IDO1TDO2CYP11B2
SCHEMBL718287 0.83 IDO1 (0.41) KDM4EALDH1A1HTTRAB9ASLC6A2
SCHEMBL718340 0.83 IDO1 (0.41) KDM4EALDH1A1HTTRAB9ASLC6A2
SCHEMBL720040 0.82 NOTUM (0.46) KDM4EALDH1A1HTTRAB9AMAPT
SCHEMBL718348 0.79 GCG (0.48)
SCHEMBL719334 0.79 BCHE (0.40) KDM4EALDH1A1HTTRAB9AIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885HTT 1337/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885HTT 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.